Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 456 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo capsules given Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects

NCT03310359
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Astaxanthin, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

NCT04000737
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Sorafenib+YIV-906, Sorafenib+placebo
Drug
Lead sponsor
Yiviva Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Flushing, New York • Lake Success, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

NCT04014387
View directory record Official record
Conditions
Progressive Supranuclear Palsy(PSP), Insomnia
Interventions
Suvorexant, Zolpidem, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia

NCT01048502
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Fenofibrate (Tricor) tablets, Placebo, Lovaza
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 9, 2026, 2:02 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

NCT04037605
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)

NCT02406066
View directory record Official record
Conditions
Cocaine Use Disorder, Tobacco Use Disorder
Interventions
metyrapone & oxazepam, Placebo
Drug
Lead sponsor
Embera NeuroTherapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Long Beach, California • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

NCT00924053
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
EGT0001474, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Early Phase 1 Interventional

Baclofen Treatment of Ataxia Telangiectasia

NCT00640003
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System

NCT06261905
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
[11C]-PHNO, Calcitriol, Placebo Control, PET Scan
Drug · Dietary Supplement · Other + 1 more
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

NCT04102501
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
RT001, Placebo
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
12 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Vitamin D in Colorectal Cancer Chemoprevention

NCT01574027
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Vitamin D3 (cholecalciferol), Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
50 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

NCT00417612
View directory record Official record
Conditions
Hypophosphatemia, Familial, Hyperparathyroidism
Interventions
Paricalcitol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
9 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Results available

A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

NCT00708201
View directory record Official record
Conditions
Postoperative Ileus
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Laguna Hills, California • Aurora, Colorado • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04622293
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions
Solriamfetol Oral Tablet [Sunosi], Placebo
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 9, 2026, 2:02 AM EDT
Terminated Phase 4 Interventional Results available

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

NCT01100437
View directory record Official record
Conditions
Chronic Pain
Interventions
EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 9, 2026, 2:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Creatine Supplementation At Simulated Altitude

NCT06489587
View directory record Official record
Conditions
Exercise Performance
Interventions
Placebo, Creatine
Dietary Supplement
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced Sep 9, 2026, 2:02 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

NCT00419562
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Oral Insulin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Iron Supplementation and Side Effects

NCT04018300
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Overload
Interventions
Ferrous sulfate, Aspiron, Placebo
Dietary Supplement · Other
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Guanfacine Clinical Trial for Smoking Cessation

NCT02051309
View directory record Official record
Conditions
Smoking Cessation
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 1 Interventional

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

NCT01290965
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Placebo, SCY-635
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Sep 9, 2026, 2:02 AM EDT
Terminated Phase 4 Interventional Results available

Low Pain Prediction in Cesarean Section Patients

NCT02143141
View directory record Official record
Conditions
Scheduled Cesarean Sections, Postoperative Pain Management, Side Effects
Interventions
duramorph, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 9, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy

NCT02541396
View directory record Official record
Conditions
Acute Pain
Interventions
Wafermine, Oxycodone, Placebo
Drug
Lead sponsor
iX Biopharma Ltd.
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 9, 2026, 2:02 AM EDT